Inhibition of human immunodeficiency virus-1 (HIV-1) by β-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis

Clinical and Experimental Immunology

Volumn 142, Issue 2, 2005, Pages 327-332

  Toossi, Zahra ^a,c   Mayanja Kizza, H ^a,d   Baseke, J ^d   Peters, P ^d   Wu, M ^a   Abraha, A ^a   Aung, H ^a   Okwera, A ^d   Hirsch, C ^a,b   Arts, E ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

chemokines; CCR5; Macrophages; RANTES analogues; Tuberculosis

Indexed keywords

BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; DNA; MESSENGER RNA; RANTES;

ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEURA FLUID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUBERCULOUS PLEURISY; VIRUS INHIBITION;

ADULT; CELLS, CULTURED; CHEMOKINES, CC; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RANTES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUBERCULOSIS; TUBERCULOSIS, PLEURAL; TUBERCULOSIS, PULMONARY;

EID: 27644533758     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02913.x     Document Type: Article

References (28)

1. Harries AD, Hargreaves NJ, Chimzizi R, Salaniponi FM. Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential. Bull WHO 2002; 80:464-9.
2. Whalen C, Horsburgh CR, Horn D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Grit Care Med 1995; 151:129-35.
3. Nunn P, Brindle R, Carpenter L et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146:849-54.
4. Whalen CC, Nsubuga P, Okwera A et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. Aids 2000; 14:1219-28.
5. Toossi Z, Mayanja-Kizza H, Hirsch CS et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001; 123:233-8.
6. Collins KR, Mayanja-Kizza H, Sullivan BA, Quinones-Mateu ME, Toossi Z, Arts EJ. Greater diversity of HIV-1 quasispecies in HIV-infected individuals with active tuberculosis. J Acquir Immune Defic Syndr 2000; 24:408-17.
7. Collins KR, Quinones-Mateu ME, Wu M et al. Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol 2002; 76:1697-706.
8. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188:1146-55.
9. Mayanja-Kizza H, Wajja A, Wu M et al. Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2001; 183:1801-4.
10. Toossi Z, Johnson JL, Kanost RA et al. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr 2001; 28:1-8.
11. Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am J Respir Cell Mol Biol 1998; 19:513-21.
12. Naruse K, Ueno M, Satoh T et al. A YAC contig of the human CC chemokine genes clustered on chromosome 17q11. 2 Genomics 1996; 34:236-40.
13. Fantuzzi L, Conti L, Gauzzi MC et al Regulation of chemokine/cytokine network during in vitro differentiation and HIV-1 infection of human monocytes: possible importance in the pathogenesis of AIDS. J Leukoc Biol 2000; 68:391-9.
14. Richter C, Perenboom R, Mtoni I et al. Clinical features of HIV-seropositive and HIV-seronegative patients with tuberculous pleural effusion in Dar es Salaam, Tanzania. Chest 1994; 106:1471-5.
15. Barnes PF, Bloch AB, Davidson PT, Snider DE. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324:1644-50.
16. Simmons G, Clapham PR, Picard L et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276:276-9.
17. Torre VS, Marozsan AJ, Albright JL et al. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 2000; 74:4868-76.
18. Pastore C, Picchio GR, Galimi F et al. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 2003; 47:509-17.
19. Kawamura T, Bruce SE, Abraha A et al. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 2004; 78:7602-9.
20. Mosier DE, Picchio GR, Gulizia RJ et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73:3544-50.
21. Marozsan AJ, Torre VS, Johnson M et al. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J Virol 2001; 75:8624-38.
22. Kelly MD, Naif HM, Adams SL, Cunningham AL, Lloyd AR. Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages. J Immunol 1998; 160:3091-5.
23. National Tuberculosis and Respiratory Disease Association. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis and Respiratory Disease Association, 1969:68-76.
24. Fassati A, Goff SP. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 2001; 75:3626-35.
25. Reeves JD, Gallo SA, Ahmad N et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99:16249-54.
26. Kuhmann SE, Pugach P, Kunstman KJ et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78:2790-807.
27. Gross E, Amelia CA, Pompucci L, Franchin G, Sherry B, Schmidtmayerova H. Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection. J Leukoc Biol 2003; 74:781-90.
28. Cho MW, Kim YB, Lee MK et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 2001; 75:2224-34.